Resonant Capital Advisors LLC Has $2.10 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Resonant Capital Advisors LLC lessened its holdings in Becton, Dickinson and Company (NYSE:BDXFree Report) by 2.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,151 shares of the medical instruments supplier’s stock after selling 270 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Becton, Dickinson and Company were worth $2,096,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in shares of Becton, Dickinson and Company by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier’s stock worth $6,067,196,000 after acquiring an additional 184,288 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in Becton, Dickinson and Company by 36.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier’s stock worth $2,751,187,000 after purchasing an additional 3,219,317 shares in the last quarter. Geode Capital Management LLC lifted its stake in Becton, Dickinson and Company by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier’s stock valued at $1,437,161,000 after purchasing an additional 66,024 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in Becton, Dickinson and Company by 15.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier’s stock valued at $1,401,126,000 after buying an additional 810,345 shares in the last quarter. Finally, First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 31.4% during the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier’s stock worth $1,004,132,000 after buying an additional 1,057,879 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Barclays dropped their price target on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a research note on Tuesday, June 3rd. Bank of America lowered Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price target on the stock. in a research note on Thursday, May 1st. Morgan Stanley lowered their price objective on Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating for the company in a research note on Tuesday, May 6th. Citigroup downgraded shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and cut their target price for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. Finally, Piper Sandler cut shares of Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $219.22.

Check Out Our Latest Report on BDX

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $177.05 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. The stock has a market capitalization of $50.74 billion, a price-to-earnings ratio of 33.79, a PEG ratio of 1.34 and a beta of 0.25. The stock’s 50 day moving average price is $175.08 and its two-hundred day moving average price is $208.50. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the firm earned $3.17 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 4.5% on a year-over-year basis. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a yield of 2.35%. The ex-dividend date was Monday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 79.39%.

Insider Activity at Becton, Dickinson and Company

In related news, EVP David Shan sold 1,166 shares of the firm’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president directly owned 4,575 shares of the company’s stock, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president owned 4,887 shares of the company’s stock, valued at approximately $964,107.36. This trade represents a 8.93% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by insiders.

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.